spacer
home > ebr > summer 2017 > in your genes
PUBLICATIONS
European Biopharmaceutical Review

In Your Genes

In April 2017, the FDA formally approved the sale of direct-to-consumer genetic testing for 10 disease indications and established a framework for future approvals. This opens up the field to consumer genetic tests that are both accurate in their readout and significant in their interpretation. It places the US market on the same playing field as Canada and UK – but the move is not without controversy.

Advances in genomics have stimulated great interest as a tool for drug discovery, as a means of disease diagnosis and treatment and as an additional way to make sense of individual prognoses. Particularly in the consumer health arena, breathtaking advances in science have captured the public imagination as a possible way to predict future health outcomes. As a sidebar, the ancestry interpretation of personal genomics has become very popular.

The recent FDA move concludes four years of restrictions placed on claims and product offerings by the personal genomics company 23andMe. This was a time to validate the accuracy of the lab work, scientific significance and clinical relevance and to address concerns about the consumer-facing documentation and interpretation. Doctors had often been faced with difficult patient questions like, ‘how much does this increase my risk?’

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, and an industry consultant, with experience in drug discovery, development and pharmaceutical outsourcing.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Oxford Genetics licenses SnapFast™ expression vectors to Twist Bioscience

November 16, 2017, Oxford, England and San Francisco, US. – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced today a new licensing agreement with Twist Bioscience Corporation, a company enabling customers to succeed through its offering of rapid, high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience with its SnapFast™ technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.
More info >>

White Papers

Quality of Steel

Natoli Engineering Company, Inc.

Steel quality is the summation of how well a steel meets its specified chemistry, the cleanliness of the steel or degree to which it is free of impurities or inclusion, homogeneity of the microstructure, grain/carbide size and in some instances if it meets the mechanical requirements for that particular steel. In the design and manufacture of tablet compression tooling, nothing is more important than the quality of the materials being used. The best manufacturing principals maintaining the tightest tolerances will result in tool failure if the initial material quality is poor. Material quality is the fundamental building block upon which all successive value added steps are laid. The majority of all tablet compression tooling is produced from steel and steel quality is the subject of this article.
More info >>

 
Industry Events

13th Annual Biomarkers Congress

15-16 February 2018, Manchester Central Convention Complex, Manchester, UK

Oxford Global is proud to present the 13th Annual Biomarkers Congress to be held on 15-16 February 2018, Manchester. The congress covers novel developments in biomarker discovery and validation, translation into the clinic, personalised healthcare, Big data management, clinical diagnostics development. Key therapeutic focus areas include Immuno Oncology, Neuroscience, Respiratory, Metabolic and Cardiovascular Diseases
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement